The Influence of Salak Skin Ethanol Extract on the Lipid Profile, Il-6 and MDA Serum (Experimental Study on Male Rats of Wistar Strains Induced by High-Fat Diet)

Abstract

Dyslipidemia is characterized by an increase in total cholesterol, triglycerides, LDL and a decrease in HDL. One of the consequences of endothelial dysfunction as a precursor to cardiovascular disease is induced by oxidative stress and inflammation, so this condition must be controlled. Dyslipidemia causes an increase in pro-inflammatory cytokines which play a role in oxidative stress and inflammatory processes. The aim of this study was to determine the effect of administering snake fruit ethanol extract on serum lipid profile, IL-6 and MDA levels in Wistar rats induced by a high-fat diet. The type of research is experimental with a Post Test Only Control Group Design research design. The research subjects used 36 Wistar rats, divided into 6 treatment groups, namely healthy control group (KS), negative control (K-), positive control with simvastatin (K+), 60 mg dose EEKS group (P1), 120 mg dose EEKS group (P2), and EEKS group dose 240 mg (P3). Examination on day 36 used blood serum ELISA method to analyze levels of lipid profile, IL-6 and MDA. There was a significant difference using the t test (p0.05) in the average decrease in total cholesterol, LDL, triglyceride levels and increase in HDL levels. The results of IL-6 levels showed significant differences between groups using the one way anova test (p0.05), the 120 mg dose had the lowest results but was not significantly different when compared to the K+ group using the post hoc LSD test (p0, 05), while the results of MDA levels were significantly different using the Kruskal Wallis test (p0.05), showing that the 240 mg dose had the same results as the simvastatin group using the Mann- Whitney test (p0.05). Snake bark ethanol extract (EEKS) at a dose of 240 mg has the same effect as simvastatin by reducing total cholesterol, LDL, triglyceride levels and increasing HDL. EEKS reduces IL-6 and MDA levels in dyslipidemia conditions.